Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.

Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.

Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.

PMID:
31685558
2.

Sub-optimality in motor planning is not improved by explicit observation of motor uncertainty.

Ota K, Shinya M, Maloney LT, Kudo K.

Sci Rep. 2019 Oct 16;9(1):14850. doi: 10.1038/s41598-019-50901-x.

3.

Low-dose material-specific radiography using monoenergetic photons.

Harms J, Maloney L, Erickson A.

PLoS One. 2019 Sep 6;14(9):e0222026. doi: 10.1371/journal.pone.0222026. eCollection 2019.

4.

Using a Journal Club Series to Introduce Paramedic Students to Research Fundamentals and Critical Appraisal of Medical Literature.

Maloney LM, Marshall RT, Werfel PA, Johnson SE.

Prehosp Disaster Med. 2019 Aug;34(4):449-453. doi: 10.1017/S1049023X19004618. Epub 2019 Jul 19.

PMID:
31322497
5.

ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.

O'Neill T, Miksad R, Miller D, Maloney L, John A, Hiller C, Hornberger J.

Value Health. 2019 Jul;22(7):754-761. doi: 10.1016/j.jval.2019.03.020. Epub 2019 Jun 8.

PMID:
31277820
6.

Generality of likelihood ratio decisions.

Glanzer M, Hilford A, Kim K, Maloney LT.

Cognition. 2019 Oct;191:103931. doi: 10.1016/j.cognition.2019.03.023. Epub 2019 Jul 2.

PMID:
31276947
7.

Efficient visual information sampling develops late in childhood.

Jones PR, Landin L, McLean A, Juni MZ, Maloney LT, Nardini M, Dekker TM.

J Exp Psychol Gen. 2019 Jul;148(7):1138-1152. doi: 10.1037/xge0000629.

PMID:
31219287
8.

Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".

Wallace K, Goble S, Isaacson J, Maloney L, Cameron T, Bedel J.

Pharmacoeconomics. 2019 Aug;37(8):1065-1067. doi: 10.1007/s40273-019-00815-3. No abstract available.

9.

Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.

Means C, Clayburgh DR, Maloney L, Sauer D, Taylor MH, Shindo ML, Coussens LM, Tsujikawa T.

Head Neck. 2019 Aug;41(8):2636-2646. doi: 10.1002/hed.25740. Epub 2019 Mar 21.

PMID:
30896061
10.

Stigma and outness about sexual behaviors among cisgender men who have sex with men and transgender women in Eswatini: a latent class analysis.

Lyons C, Stahlman S, Holland C, Ketende S, Van Lith L, Kochelani D, Mavimbela M, Sithole B, Maloney L, Maziya S, Baral S.

BMC Infect Dis. 2019 Mar 5;19(1):211. doi: 10.1186/s12879-019-3711-2.

11.

Honest Disclosure of Conflicts of Interest Advances Emergency Medicine Scholarship.

Maloney LM, Mycyk MB.

Acad Emerg Med. 2019 Jun;26(6):698-700. doi: 10.1111/acem.13718. Epub 2019 Mar 19. No abstract available.

PMID:
30802334
12.

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.

Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.

13.

One mirror effect: The regularities of recognition memory.

Hilford A, Glanzer M, Kim K, Maloney LT.

Mem Cognit. 2019 Feb;47(2):266-278. doi: 10.3758/s13421-018-0864-y.

PMID:
30288686
14.

Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia.

Monroe K, Cohen CT, Whelan K, King A, Maloney L, Deason J, Nichols JC, Friedman GK, Kutny M, Hayes L.

Pediatr Qual Saf. 2018 Aug 9;3(4):e095. doi: 10.1097/pq9.0000000000000095. eCollection 2018 Jul-Aug.

15.

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Shapiro GI, Kristeleit RS, Burris HA, LoRusso P, Patel MR, Drew Y, Giordano H, Maloney L, Watkins S, Goble S, Jaw-Tsai S, Xiao JJ.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):107-118. doi: 10.1002/cpdd.575. Epub 2018 May 25.

16.

Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials.

Fuller JT, Hartland MC, Maloney LT, Davison K.

Br J Sports Med. 2018 Oct;52(20):1311. doi: 10.1136/bjsports-2017-098285. Epub 2018 Mar 16. Review.

PMID:
29549149
17.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators.

Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Erratum in: Lancet. 2017 Oct 28;390(10106):1948.

18.

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.

Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.

19.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

20.

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.

Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.

Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.

21.

Integration of a Low-Cost Introductory Ultrasound Curriculum Into Existing Procedural Skills Education for Preclinical Medical Students.

Maloney L, Zach K, Page C, Tewari N, Tito M, Seidman P.

J Ultrasound Med. 2017 Feb;36(2):367-373. doi: 10.7863/ultra.16.03108. Epub 2016 Dec 27.

PMID:
28026892
22.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.

Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

23.

Information sampling behavior with explicit sampling costs.

Juni MZ, Gureckis TM, Maloney LT.

Decision (Wash D C ). 2016 Jul;3(3):147-168.

24.

Gambling on visual performance: neural correlates of metacognitive choice between visual lotteries.

Wu SW, Delgado MR, Maloney LT.

Front Neurosci. 2015 Sep 3;9:314. doi: 10.3389/fnins.2015.00314. eCollection 2015.

25.

Allocentric kin recognition is not affected by facial inversion.

Dal Martello MF, DeBruine LM, Maloney LT.

J Vis. 2015;15(13):5. doi: 10.1167/15.13.5.

26.

Human representation of visuo-motor uncertainty as mixtures of orthogonal basis distributions.

Zhang H, Daw ND, Maloney LT.

Nat Neurosci. 2015 Aug;18(8):1152-8. doi: 10.1038/nn.4055. Epub 2015 Jun 29.

27.

The efficiency of vision and action.

Verghese P, Maloney LT, Landy MS.

Vision Res. 2015 Aug;113(Pt B):113-5. doi: 10.1016/j.visres.2015.06.003. Epub 2015 Jun 18. No abstract available.

28.

Acquisition, representation, and transfer of models of visuo-motor error.

Zhang H, Kulsa MK, Maloney LT.

J Vis. 2015;15(8):6. doi: 10.1167/15.8.6.

29.

Three regularities of recognition memory: the role of bias.

Hilford A, Maloney LT, Glanzer M, Kim K.

Psychon Bull Rev. 2015 Dec;22(6):1646-64. doi: 10.3758/s13423-015-0829-0. Review.

PMID:
25933627
30.

Revealing individual differences in strategy selection through visual motion extrapolation.

Fulvio JM, Maloney LT, Schrater PR.

Cogn Neurosci. 2015;6(4):169-79. doi: 10.1080/17588928.2014.1003181. Epub 2015 Feb 5.

PMID:
25654543
31.

Neural mechanisms for integrating prior knowledge and likelihood in value-based probabilistic inference.

Ting CC, Yu CC, Maloney LT, Wu SW.

J Neurosci. 2015 Jan 28;35(4):1792-805. doi: 10.1523/JNEUROSCI.3161-14.2015.

32.

Decision from Models: Generalizing Probability Information to Novel Tasks.

Zhang H, Paily JT, Maloney LT.

Decision (Wash D C ). 2015 Jan;2(1):39-53.

33.

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R.

Clin Cancer Res. 2015 Mar 1;21(5):985-94. doi: 10.1158/1078-0432.CCR-14-1765. Epub 2014 Dec 5.

34.

The irrationality of categorical perception.

Fleming SM, Maloney LT, Daw ND.

J Neurosci. 2013 Dec 4;33(49):19060-70. doi: 10.1523/JNEUROSCI.1263-13.2013.

35.

Inferred motion perception of light sources in 3D scenes is color-blind.

Gerhard HE, Maloney LT.

Iperception. 2013 Mar 8;4(2):98-100. doi: 10.1068/i0591sas. Print 2013.

36.

Testing whether humans have an accurate model of their own motor uncertainty in a speeded reaching task.

Zhang H, Daw ND, Maloney LT.

PLoS Comput Biol. 2013;9(5):e1003080. doi: 10.1371/journal.pcbi.1003080. Epub 2013 May 23.

37.

Very slow search and reach: failure to maximize expected gain in an eye-hand coordination task.

Zhang H, Morvan C, Etezad-Heydari LA, Maloney LT.

PLoS Comput Biol. 2012;8(10):e1002718. doi: 10.1371/journal.pcbi.1002718. Epub 2012 Oct 11.

38.

Speeded reaching movements around invisible obstacles.

Hudson TE, Wolfe U, Maloney LT.

PLoS Comput Biol. 2012;8(9):e1002676. doi: 10.1371/journal.pcbi.1002676. Epub 2012 Sep 20.

39.

Effective integration of serially presented stochastic cues.

Juni MZ, Gureckis TM, Maloney LT.

J Vis. 2012 Aug 21;12(8). pii: 12. doi: 10.1167/12.8.12.

40.

Optimizing multiscale SSIM for compression via MLDS.

Charrier C, Knoblauch K, Maloney LT, Bovik AC, Moorthy AK.

IEEE Trans Image Process. 2012 Dec;21(12):4682-94. doi: 10.1109/TIP.2012.2210723. Epub 2012 Jul 30.

41.

Do ward housekeepers free up time for care?

Tye L, Urmson S, Maloney L.

Nurs Times. 2012 Feb 28-Mar 5;108(9):19.

PMID:
22479768
42.

Comparison of the distortion of probability information in decision under risk and an equivalent visual task.

Glaser C, Trommershäuser J, Mamassian P, Maloney LT.

Psychol Sci. 2012 Apr;23(4):419-26. doi: 10.1177/0956797611429798. Epub 2012 Mar 6.

43.

Human visual search does not maximize the post-saccadic probability of identifying targets.

Morvan C, Maloney LT.

PLoS Comput Biol. 2012 Feb;8(2):e1002342. doi: 10.1371/journal.pcbi.1002342. Epub 2012 Feb 2.

44.

Visual extrapolation under risk: human observers estimate and compensate for exogenous uncertainty.

Warren PA, Graf EW, Champion RA, Maloney LT.

Proc Biol Sci. 2012 Jun 7;279(1736):2171-9. doi: 10.1098/rspb.2011.2527. Epub 2012 Feb 1.

45.

Ubiquitous log odds: a common representation of probability and frequency distortion in perception, action, and cognition.

Zhang H, Maloney LT.

Front Neurosci. 2012 Jan 19;6:1. doi: 10.3389/fnins.2012.00001. eCollection 2012.

46.

High cell density attenuates reactive oxygen species: implications for in vitro assays.

Kim DP, Yahav J, Sperandeo M, Maloney L, McTigue M, Lin F, Clark RA.

Wound Repair Regen. 2012 Jan-Feb;20(1):74-82. doi: 10.1111/j.1524-475X.2011.00746.x. Epub 2011 Nov 22.

PMID:
22107255
47.

The neural correlates of subjective utility of monetary outcome and probability weight in economic and in motor decision under risk.

Wu SW, Delgado MR, Maloney LT.

J Neurosci. 2011 Jun 15;31(24):8822-31. doi: 10.1523/JNEUROSCI.0540-11.2011. Erratum in: J Neurosci. 2011 Jul 6;31(27):10115.

48.

Visual perception of thick transparent materials.

Fleming RW, Jäkel F, Maloney LT.

Psychol Sci. 2011 Jun;22(6):812-20. doi: 10.1177/0956797611408734. Epub 2011 May 19.

PMID:
21597102
49.

Surface color perception and equivalent illumination models.

Brainard DH, Maloney LT.

J Vis. 2011 May 2;11(5). pii: 1. doi: 10.1167/11.5.1. Review.

50.

Directional bias in the body while walking through a doorway: its association with attentional and motor factors.

Fujikake H, Higuchi T, Imanaka K, Maloney LT.

Exp Brain Res. 2011 Apr;210(2):195-206. doi: 10.1007/s00221-011-2621-3. Epub 2011 Mar 16.

PMID:
21409408

Supplemental Content

Loading ...
Support Center